Exercise For Fighting Oncology Repercussions After Treatment

Neoplasms Clinical Trial

— EFFORT  

Official title:

Exercise For Fighting Oncology Repercussions After Treatment: the EFFORT Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05980325
• Other study ID #: TCM-EFFORTv3
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 1, 2024
• Est. completion date: July 1, 2025

Study information

• Verified date: August 2023
• Source: Universitat Pompeu Fabra
• Contact: Esther Mur Gimeno, PhD
• Phone: +34931696573
• Email: emur[@]tecnocampus.cat
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cancer survival rates are currently on the verge of 70% at 5 years since diagnosis. Recent improvements in main cancer therapies including chemotherapy, radiotherapy, surgery and immunotherapy as well as developments of new biological therapies have significantly improved survival rates but unfortunately, cancer-related side effects continue to affect many patients even years after completion of main treatments. Exercise has been shown to not only ameliorate cancer-related effects before, during and after treatment but also improve disease-free and overall survival rates by decreasing risk factors associated with cancer risk and improving resilience to treatment. In this non-randomised, three-arm study, we aim to assess the effects of three forms of exercise (i.e: Nordic Walking, Aquatic Exercise and Functional Exercise) on physical performance, cancer-related fatigue, health-related quality of life and cancer-specific symptoms in a wide range of cancer survivors.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 45
• Est. completion date: July 1, 2025
• Est. primary completion date: January 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adults diagnosed with cancer

• Completion of any cancer therapy in the previous 3 months with the exception of hormonal therapy

• Patients living within the Maresme Area

• No contraindications for exercise (oncology clearance or Physical Activity Readiness Questionnaire negative)

Exclusion Criteria:

• Patients with any neurologic, cognitive or musculoskeletal impairments that prevent them to engage in any assessment test or exercise modality.

• Patients with unstable cardiac, respiratory or metabolic diseases

• Unable to speak or read Catalan or Spanish

Related Conditions & MeSH terms

• Neoplasms

Intervention

Behavioral:
• Nordic Walking
A 12-week Nordic Walking exercise programme supervised twice weekly
• Aquatic Exercise
A 12-week water-based exercise training programme supervised twice weekly
• Functional Exercise Training
A 12-week circuit-based exercise training programme supervised twice weekly

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
Universitat Pompeu Fabra	Ajuntament de Mataró, Col·legi de Fisioterapeutes de Catalunya

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Health-Related Quality of Life	HRQoL measured with the EORTC Quality of Life C30 questionnaire	12 weeks from baseline
Secondary	Cancer-related fatigue	Cancer-related fatigue as measure with the Brief Fatigue Inventory	12 weeks from baseline
Secondary	Cardiorespiratory fitness	A steady state cardiopulmonary exercise testing with breath-by-breath analysis and lactate measurement to determine submaximal cardiorespiratory fitness	12 weeks from baseline
Secondary	Estimated one-repetition maximum	Estimated maximal muscle strength using a linear Encoder for two main muscle groups: i) chest and ii) quads	12 weeks from baseline
Secondary	Lower limb muscle endurance	Lower limb muscle endurance measured as the maximum number of sit-to-stand repetitions performed in 30 seconds	12 weeks from baseline
Secondary	Functional capacity	Walking distance covered during a self-pace 6 minute walk test	12 weeks from baseline